Related Experiment Video
Updated: Jun 17, 2025

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
Squamous Cell Carcinoma in Never Smokers: An Insight into SMARCB1 Loss
Akshay J Patel1,2, Hanan Hemead2, Hannah Jesani2
1Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK.
Lung cancer in never smokers with squamous cell carcinoma (SqCC) is aggressive. SMARCB1-deficient SqCC in never smokers shows rapid progression and poor survival, necessitating targeted therapies.
Area of Science:
- Oncology
- Genomics
- Thoracic Surgery
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with squamous cell carcinoma (SqCC) linked to smoking.
- Lung cancer in never smokers (LCINS), particularly LCINS-SqCC, is increasing and less understood regarding genomic drivers and outcomes.
Purpose of the Study:
- To investigate the genomic alterations and clinical outcomes of lung cancer in never smokers with squamous cell carcinoma (LCINS-SqCC).
- To identify specific molecular subtypes and their prognostic implications in this understudied population.
- To inform personalized treatment strategies for LCINS-SqCC.
Main Methods:
- Retrospective analysis of 59 LCINS-SqCC patients undergoing radical surgical resection over 20 years (2003-2023) at two UK tertiary centers.
- Collection of demographic, comorbidity, histopathological, and survival data.
- Molecular sequencing of tumor specimens to identify genomic aberrations.
Main Results:
- Median patient age was 71 years, with a slight male predominance.
- Disease recurrence occurred in 39% of patients, and 54% died within 3 years.
- Biallelic SMARCB1 loss was identified in two younger patients, associated with rapid progression, PDL1-negativity, and specific immunophenotype (cytokeratin+, CD56+, p40+).
Conclusions:
- SMARCB1-deficient SqCC in never smokers is a highly aggressive variant with poor disease-free survival.
- Advanced molecular diagnostics are crucial for identifying this aggressive subtype.
- Personalized treatment strategies, including EZH2 inhibitors and immune checkpoint blockade, are needed for SMARCB1-deficient lung cancers.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Cancers Originate from Somatic Mutations in a Single Cell
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation
Cancer Prevention
Some...

